SF3B1 and myelodysplastic syndrome: In hematological tumors, more than half of patients with myelodysplastic syndromes (MDS) show mutations in functional components of the spliceosome, commonly in serine-rich SFs, such as SF3B1, SRSF2, and U2AF1 [16].